Trials / Terminated
TerminatedNCT01677390
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-75 | 1-2 mg/kg IV every 21 days |
| DRUG | everolimus | 10 mg PO daily |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2012-09-03
- Last updated
- 2014-01-28
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01677390. Inclusion in this directory is not an endorsement.